Departments of Internal Medicine, Clínica San Camilo, Alfredo Bufano 2423, 1416 Buenos Aires, Argentina.
Rheumatol Int. 2012 Jan;32(1):273-5. doi: 10.1007/s00296-010-1786-6. Epub 2011 Jan 18.
Human cytomegalovirus (CMV) is responsible for significant morbidity and mortality in immunocompromised populations, such as those suffering from dermatomyositis (DM). We present here a case study of a DM patient undergoing methotrexate treatment who presents with weakness, myalgia, elevated levels of hepatic transaminases and serological markers of CMV primo-infection. The antiviral activity of leflunomide against CMV was described recently. The use of leflunomide as an immunomodulator may have contributed to the satisfactory evolution of the treatment for a symptomatic CMV infection in an immunocompromised patient, since the typical treatment outcome is more prolonged and with additional complications.
人巨细胞病毒（CMV）是导致免疫功能低下人群（如皮肌炎（DM）患者）发病率和死亡率显著增加的主要病原体。我们在此报告一例正在接受甲氨蝶呤治疗的皮肌炎患者，该患者出现乏力、肌痛、肝转氨酶水平升高和 CMV 原发感染的血清学标志物。最近描述了来氟米特对 CMV 的抗病毒活性。来氟米特作为免疫调节剂的使用可能有助于免疫功能低下患者的 CMV 感染症状得到满意的治疗，因为典型的治疗结果持续时间更长，且伴有额外的并发症。
